Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated.

STUDY OBJECTIVES

Primary: Objective response rate

Secondary: Progression free survival, Overall survival and Safety of Tarceva
Non-Small Cell Lung Cancer
DRUG: Tarceva (erlotinib)
Objective response rate
Progression free survival|Overall survival|Safety of Tarceva
Study Design: Phase II trial, open label, non-randomized and multicenter.

Expected total enrollment: 46

Study start: January, 2006

Study completation: January, 2008